A randomised 2 x 2 factorial study of aspirin versus placebo, and of omega-3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes

niversity of Oxford (UK)0 个研究点目标入组 15,480 人开始时间: 2005年9月1日最近更新: 2023年10月9日

适应症

试验速览

2016 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/27296091 recruitment methods 2018 Results article in http://www.ncbi.nlm.nih.gov/pubmed/29653635 results (added 01/02/2019) 2018 Results article in http://www.ncbi.nlm.nih.gov/pubmed/30146932 results (added 07/05/2019) 2018 Results article in http://www.ncbi.nlm.nih.gov/pubmed/30146931 results (added 07/05/2019) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36871000/ (added 06/03/2023) 2023 Results article in https://doi.org/10.1136/heartjnl-2023-322616 (added 05/06/2023) 2023 Results article in https://doi.org/10.1016/j.conctc.2023.101184 ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial (added 25/09/2023)

•The following point has been amended as of 11/02/2009:
•2. Currently prescribed warfarin
•Initial information at time of registration:
•1. Definite history of myocardial infarction, stroke or arterial revascularisation procedure
•2. Currently prescribed aspirin, warfarin or any other blood thinning medication

发起方

niversity of Oxford (UK)